.jpg?format=webp&width=780)
To assess the change in HbA1c after initiation of biosimilar follow‐on insulin (Basaglar) or reference insulin (Lantus) among patients with type 2 diabetes. The study also compared treatment adherence, safety events and costs at 1 year after initiation of insulin. In patients with type 2 diabetes, Basaglar provided similar glycaemic control compared with Lantus, had a similar safety profile and lower drug costs, and showed more favourable adherence.
Like
Save
Share